Endo announced that it has completed the previously announced divestiture of its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc.
Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid at closing, approximately $11 million related to certain permitted holdbacks, and up to $15 million in future payments contingent upon the achievement of certain milestones.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!